ANKDD1A

Across TCGA pan-cancer cohorts, ANKDD1A RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of ANKDD1A’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ANKDD1A RNA is repressed in tumor relative to normal tissue. In most cancer types ANKDD1A is over-expressed in tumor, although a few such as THCA and LUAD show the opposite, repressed pattern.

THCA, KIRC, and LUAD are the cancer types where ANKDD1A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ANKDD1A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	IV	−1.386	<.001	11	view →
KIRC	Male	All	+0.390	<.001	8	view →
LUAD	Female	II,III,IV	−0.711	<.001	7	view →
LIHC	All	All	+0.368	<.001	7	view →
UCEC	All	All	−1.368	<.001	6	view →
BRCA	All	All	−1.064	<.001	6	view →
CHOL	Female	All	+2.106	<.001	5	view →
LUSC	Female	II,III,IV	−1.031	<.001	5	view →
PRAD	All	All	−0.689	<.001	2	view →
KICH	All	All	−0.438	<.001	2	view →
COAD	Male	All	−0.392	.004	2	view →
BLCA	Male	III,IV	−0.742	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

ANKDD1A–THCA

Open the THCA breakdown →